Top Line: Does shaving a week off treatment with 6 fractions per week improved outcomes for locally advanced HNSCC in the setting of concurrent chemotherapy?
The Study: Accelerated fractionation has long been a consideration to outpace tumor repopulation in head and neck cancer. Classic trials from the DAHANCA 6/7 era showed improved locoregional control with 6 fractions per week versus 5, but mostly without concurrent chemo and in earlier stage disease. Later phase 3 trials like RTOG 0129 and GORTEC 99-02 attempted to combine altered fractionation with chemoradiation, but differences in RT schedules, chemotherapy intensity, and boost designs muddied the waters with neither demonstrating a clear tumor control or survival advantage for acceleration. Enter this nationwide Swedish cohort study (n=940), leveraging region-specific treatment traditions as a quasi-randomized “natural experiment.” Patients with locally advanced HNSCC (≤70 y) received definitive RT (68 Gy in 34 fractions) delivered either 5fx/w or 6fx/w. Most patients received concurrent weekly cisplatin (79% vs 66%). At 5 years, LRC improved with 6fx/w (84% vs 78%; HR 0.69), corresponding to a roughly 6% absolute benefit. Overall survival was unchanged (67% vs 66%; HR 0.93). The benefit appeared larger in p16-negative disease, where absolute LRC gains approached roughly 10%.
TBL: This real-world cohort suggests a locoregional control benefit with 6fx/w radiation in the setting of concurrent chemotherapy for locally advanced HNSCC, particularly among those with p16 negative disease. | Adrian, Radiother Oncol 2026
The Study: Accelerated fractionation has long been a consideration to outpace tumor repopulation in head and neck cancer. Classic trials from the DAHANCA 6/7 era showed improved locoregional control with 6 fractions per week versus 5, but mostly without concurrent chemo and in earlier stage disease. Later phase 3 trials like RTOG 0129 and GORTEC 99-02 attempted to combine altered fractionation with chemoradiation, but differences in RT schedules, chemotherapy intensity, and boost designs muddied the waters with neither demonstrating a clear tumor control or survival advantage for acceleration. Enter this nationwide Swedish cohort study (n=940), leveraging region-specific treatment traditions as a quasi-randomized “natural experiment.” Patients with locally advanced HNSCC (≤70 y) received definitive RT (68 Gy in 34 fractions) delivered either 5fx/w or 6fx/w. Most patients received concurrent weekly cisplatin (79% vs 66%). At 5 years, LRC improved with 6fx/w (84% vs 78%; HR 0.69), corresponding to a roughly 6% absolute benefit. Overall survival was unchanged (67% vs 66%; HR 0.93). The benefit appeared larger in p16-negative disease, where absolute LRC gains approached roughly 10%.
TBL: This real-world cohort suggests a locoregional control benefit with 6fx/w radiation in the setting of concurrent chemotherapy for locally advanced HNSCC, particularly among those with p16 negative disease. | Adrian, Radiother Oncol 2026